Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

BACKGROUND: Clostridium difficile infection is the most common health-care-associated infection in the USA. We assessed the safety and efficacy of ridinilazole versus vancomycin for treatment of C difficile infection. METHODS: We did a phase 2, randomised, double-blind, active-controlled, non-inferi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vickers, Richard J, Tillotson, Glenn S, Nathan, Richard, Hazan, Sabine, Pullman, John, Lucasti, Christopher, Deck, Kenneth, Yacyshyn, Bruce, Maliakkal, Benedict, Pesant, Yves, Tejura, Bina, Roblin, David, Gerding, Dale N, Wilcox, Mark H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483507/
https://www.ncbi.nlm.nih.gov/pubmed/28461207
http://dx.doi.org/10.1016/S1473-3099(17)30235-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483507/
https://www.ncbi.nlm.nih.gov/pubmed/28461207
http://dx.doi.org/10.1016/S1473-3099(17)30235-9

Ejemplares similares